ADVFN Logo
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover
Premium Connexion/S'inscrire Profile Icon
CAC 40
7 346,15
(
0,48%
)
Dow Jones
36 245,50
(
0,82%
)
DAX
16 397,52
(
1,12%
)
Brent Oil
79,125
(
0,0%
)
Bitcoin
39 519,79
(
0,12%
)
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Palatin Technologies Inc New (PTN)

  7. Palatin Technologies Inc New (PTN) Actualités

PTN Palatin Technologies Inc New

2,22
0,22 (11,0%)
02 Déc 2023 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Palatin Technologies Inc New PTN AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,22 11,0% 2,22 01:45:38
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,95 1,95 2,22 2,22 2,00
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/12/202321:52EDGAR2Form 144 - Report of proposed sale of securities
14/11/202313:30PRNUSPalatin Reports First Quarter Fiscal Year 2024 Financial..
09/11/202313:30PRNUSPalatin to Report First Quarter Fiscal Year 2024 Results;..
24/10/202322:50PRNUSPalatin Announces Closing of $5 Million Registered Direct..
24/10/202322:05EDGAR2Form 8-K - Current report
24/10/202320:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/10/202313:30PRNUSPalatin Announces $5 Million Registered Direct Offering
19/10/202314:01EDGAR2Form 8-K - Current report
19/10/202313:30PRNUSPalatin Announces Preliminary Quarter Ended September 30,..
18/10/202313:30PRNUSPalatin Announces Positive Preclinical Data Showing..
16/10/202313:30PRNUSPalatin Presents Data at the United European..
13/10/202322:31EDGAR2Form 8-K - Current report
13/10/202322:15PRNUSPalatin Receives Notice of Non-Compliance from NYSE American
28/9/202314:02EDGAR2Form 8-K - Current report
28/9/202314:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
28/9/202313:30PRNUSPalatin Reports Fourth Quarter and Fiscal Year Ended 2023..
22/9/202322:00PRNUSPalatin to Report Fourth Quarter and Fiscal Year End 2023..
08/9/202314:00EDGAR2Form 8-K - Current report
07/9/202322:00PRNUSPalatin to Present at the H.C. Wainwright 25th Annual Global..
07/9/202314:49EDGAR2Form 8-K - Current report
07/9/202313:30PRNUSPalatin Completes Enrollment in Phase 3 MELODY-1 Study of..
17/8/202303:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202314:15EDGAR2Form 8-K - Current report
10/8/202313:30PRNUSPalatin Initiates Clinical Program for Bremelanotide..
08/8/202314:00EDGAR2Form 8-K - Current report
08/8/202313:30PRNUSPalatin's Vyleesi® Licensee Fosun Pharma Reports First..
07/8/202314:00EDGAR2Form 8-K - Current report
07/8/202313:30PRNUSPalatin Announces Direct-to-Consumer Telehealth Partnership..
04/8/202314:00EDGAR2Form 8-K - Current report
04/8/202313:30PRNUSPalatin to Participate in Canaccord Genuity's 43rd Annual..
11/7/202314:25EDGAR2Form 8-K - Current report
11/7/202313:30PRNUSPalatin Announces Preliminary Fourth Quarter Fiscal 2023..
30/5/202313:30PRNUSPalatin Presents Preclinical Diabetic Nephropathy Data at..
16/5/202313:30PRNUSPalatin Reports Third Quarter Fiscal Year 2023 Financial..
11/5/202322:15PRNUSPalatin to Report Third Quarter Fiscal Year 2023 Results;..
09/5/202313:30PRNUSPalatin Presents PL8177 Ulcerative Colitis Data at Digestive..
08/5/202322:04PRNUSPalatin Invites Investors to Listen to Replay of the PL9643..
01/5/202322:00PRNUSPalatin Technologies to Host Key Opinion Leader Webinar
27/4/202313:30PRNUSPalatin Presents Initial Dry Eye Disease Phase 3 Clinical..
25/4/202313:30PRNUSPalatin Presents Data at the Association of Research in..
19/4/202313:30PRNUSPalatin Announces Preliminary Third Quarter Fiscal 2023..
18/4/202313:30PRNUSPre-Clinical Data of Palatin's Melanocortin Agonist..
02/3/202313:30PRNUSFrontiers in Immunology Publishes Pre-Clinical Study of..
28/2/202313:30PRNUSPalatin Issued Patent on Vyleesi® (Bremelanotide Injection)..
15/2/202313:30PRNUSPalatin Reports Second Quarter Fiscal Year 2023 Financial..
10/2/202313:30PRNUSPalatin to Report Second Quarter Fiscal Year 2023 Results;..
19/1/202313:30PRNUSPalatin Initiates Enrollment in the Phase 2 Bremelanotide..
18/1/202313:30PRNUSPalatin Receives $4.7 Million of Non-Dilutive Funding
10/1/202313:30PRNUSFrontiers in Immunology Publishes Pre-Clinical Study of..

Dernières Valeurs Consultées

AMEX
PTN
Palatin Technologies
Delayed Upgrade Clock

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Support: support@advfn.fr